TTSC - Overview: Thrombin Time (Bovine), Plasma
Detecting or excluding the presence of heparin or heparin-like anticoagulants (which act by enhancing antithrombin's inhibition of thrombin and other procoagulant enzymes) when used in conjunction with the reptilase time (RT) in evaluating...
DHR - Overview: Dihydrorhodamine Flow Cytometric Test, Blood
Evaluation of chronic granulomatous disease (CGD), X-linked and autosomal recessive forms, Rac2 deficiency, complete myeloperoxidase deficiency Monitoring chimerism and nicotinamide adenine dinucleotide phosphate oxidase (NOX) function...
ALUPI - Overview: Lupus Anticoagulant Profile, Technical Interpretation
Technical interpretation of testing to confirm or exclude the presence of lupus anticoagulant (LAC) Distinguishing LAC from specific coagulation factor inhibitors and nonspecific inhibitors Investigating a prolonged activated...
MPO - Overview: Myeloperoxidase Antibodies, IgG, Serum
Evaluating patients with clinical features anti-neutrophil cytoplasmic antibody associated vasculitis, specifically granulomatosis with polyangiitis, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis...
AATHI - Overview: Thrombophilia Profile Interpretation
Interpretation of testing performed as part of a profile to evaluate patients with thrombosis or hypercoagulability states including detecting a lupus-like anticoagulant; dysfibrinogenemia; disseminated intravascular...
PR3 - Overview: Proteinase 3 Antibodies, IgG, Serum
Evaluating patients with clinical features of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, specifically granulomatosis with polyangiitis (GPA), microscopic polyangiitis, and eosinophilic granulomatosis with...
HEPTP - Overview: Heparin Anti-Xa, Plasma
Measuring heparin concentration: -In patients treated with low-molecular-weight heparin preparations -In the presence of prolonged baseline activated partial thromboplastin time (APTT) (eg, lupus anticoagulant, "contact factor" deficiency,...
PCAG - Overview: Protein C Antigen, Plasma
Differentiating congenital type I protein C deficiency from type II deficiency Evaluating the significance of decreased functional protein C, especially when decreased protein C activity might be congenital rather than acquired (eg, due...
AATHR - Overview: Thrombophilia Profile, Plasma and Whole Blood
Evaluating patients with thrombosis or hypercoagulability states Detecting a lupus-like anticoagulant; dysfibrinogenemia; disseminated intravascular coagulation/intravascular coagulation and fibrinolysis Detecting a deficiency of...
VORI - Overview: Voriconazole, Serum
Monitoring trough levels of voriconazole is suggested for: -Individuals with reduced liver function -Individuals with cytochrome P450 (CYP) 2C19 alterations associated with poor metabolic function -Patients taking other medications that...
Activity Metrics Dashboard - Insights
We are excited to share that the Activity Metrics Dashboard is now live on mayocliniclabs.com. We heard your feedback and created these reports to provide a more integrated, intuitive and customized experience...
https://news.mayocliniclabs.com/file-activity-metrics-qrg/
Activity Metrics Quick Reference Guide 800-533-1710 mayocliniclabs.com Effective Date: 9/26/2024 Log in to Activity Metrics 1. On MayoClinicLabs.com, at top right, click My Dashboard. 2. Enter...
Active Learning: Connecting Teachers and Learners - Insights
Specialist in the Department of Laboratory Medicine and Pathology at Mayo Clinic, discusses how to use active learning to better connect teachers and learners....
Disaccharidase Activity Panel [Test in Focus] - Insights
Pua Hopson, D.O., discusses Mayo Clinic Labs’ new disaccharidase activity panel, which measures levels of five digestive enzymes to identify deficiencies that cause carbohydrate maldigestion and can lead...disease or inflammatory bowel...
https://news.mayocliniclabs.com/file-activity-metrics-user-guide/
Activity Metrics User’s Guide Release 1.21 Page 2 9/26/24 Activity Metrics User’s Guide TABLE OF CONTENTS Introduction ............................................................................